C
Chloe Orkin
Researcher at Queen Mary University of London
Publications - 229
Citations - 14129
Chloe Orkin is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Viral load & Medicine. The author has an hindex of 48, co-authored 202 publications receiving 11614 citations. Previous affiliations of Chloe Orkin include Barts Health NHS Trust & St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO).
David A. Wohl,Chloe Orkin,Manuela Doroana,José Henrique Pilotto,Somnuek Sungkanuparph,Patrick Yeni,Simon Vanveggel,Henri Deckx,Katia Boven +8 more
TL;DR: Rilpivirine had little effect on 25( OH)D, whereas efavirenz resulted in a significant reduction in 25(OH)D levels and an increase in the risk of severe 25(oh)D deficiency.
Journal ArticleDOI
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK
Philippa Easterbrook,Andrew N. Phillips,Teresa Hill,Ryanne Matthias,Martin Fisher,Brian Gazzard,RJ Gilson,G. Scullard,Margaret Johnson,David Dunn,Chloe Orkin,Jane Anderson,Achim Schwenk,Clifford Leen,Caroline A. Sabin +14 more
TL;DR: The patterns of antiretroviral drug use at treatment initiation from 1996 to 2005 in a large UK multicentre cohort are described.
Journal ArticleDOI
Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
Gerd Fätkenheuer,Claudine Duvivier,Armin Rieger,J. Durant,David Rey,W. Schmidt,Andrew Hill,Y van Delft,Stephan Marks,N. Vetter,R. Greil,Court Pedersen,M. Storgaard,Philippe Morlat,Christine Katlama,L. Cotte,C. Duvvier,Stefan Esser,C. Stellbrink,M. Stoll,Christoph Stephan,Albrecht Stoehr,Juergen K. Rockstroh,Dénes Bánhegyi,L. Itzchak,E. Shahar,S. Maayan,Dan Turner,Adriano Lazzarin,Andrea Antinori,G. Carosi,Lorenzo Minoli,G. Di Perri,Gaetano Filice,M. Andreoni,D. Duiculescu,Sorin Rugină,S. Erscoiu,A. Streinu,A. Pronin,Vadim Pokrovsky,B. Gruzdev,A. Yakovlev,E. Voronin,B Clotet,Gatell Jm,Jose R. Arribas,Daniel Podzamczer,Pere Domingo,C. Miralles Alvarez,J. Hernandez Quero,Hansjakob Furrer,J. Feher,Margaret A. Johnson,Julie Fox,Mark T. Nelson,M Fisher,Chloe Orkin +57 more
TL;DR: In the SENSE trial, first-line treatment with 400 mg of etravirine once daily plus two nucleoside analogues led to fewer grade 3 or 4 lipid elevations compared with efavirenz plus three nucleosid analogues.
Journal ArticleDOI
Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.
Chloe Orkin,Josep M. Llibre,S. Gallien,A. Antinori,G. M.N. Behrens,G. M.N. Behrens,Andrew Carr +6 more
TL;DR: Only strategies demonstrating noninferior efficacy, a benefit in safety/tolerability, and a favourable cost‐efficacy ratio, preferably in a single pill, will eventually match the current SOC of triple ARV therapy.
Journal ArticleDOI
Data linkage reduces loss to follow-up in an observational HIV cohort study.
Teresa Hill,Loveleen Bansi,Caroline A. Sabin,Andrew N. Phillips,David Dunn,Jane Anderson,Philippa Easterbrook,Martin Fisher,Brian Gazzard,Richard Gilson,Margaret A. Johnson,Clifford Leen,Chloe Orkin,Achim Schwenk,John Walsh,Alan Winston,Abdel Babiker,Valerie Delpech +17 more
TL;DR: Patients returning were more likely to have started highly active antiretroviral therapy, to have higher CD4 counts and viral loads, to be younger, and to have had more CD4 tests before LFU, than those permanently LFU.